Norepinephrine News and Research

RSS

Histamine is key to narcolepsy

Narcolepsy is a disorder of sleep regulation that affects control of wakefulness and sleep and renders the patient subject to disabling sleepiness during the day.

23 Sep 2004

European positive for Cymbalta and Xeristar

Eli Lilly and Company and Boehringer Ingelheim have announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes.

20 Sep 2004

Yentreve available in Europe for treatment of stress urinary incontinence

Yentreve (duloxetine hydrochloride) is now available in certain European countries, giving women suffering from moderate to severe stress urinary incontinence (SUI) a pharmaceutical treatment option for the first time.

13 Sep 2004

Cymbalta approved for diabetic peripheral neuropathy pain

The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy.

8 Sep 2004

Cymbalta, treatment for major depression hits the market

Cymbalta, a new treatment for major depression, is now available by prescription in pharmacies across the United States, Eli Lilly and Company has announced.

26 Aug 2004

Cymbalta, a new treatment for major depression

Cymbalta, a new treatment for major depression, is now available by prescription in pharmacies across the United States, Eli Lilly and Company have announced.

25 Aug 2004

Approval of Cymbalta for treatment of major depressive disorder

The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl; pronounced SIM-BALL-TA), judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Company have announced.

5 Aug 2004

Duloxetine reduces stress urinary incontinence and improves quality of life for women

Data presented today at the 3rd International Consultation on Incontinence, provide evidence for the efficacy of duloxetine, an investigational agent for the treatment of women with stress urinary incontinence (SUI).

29 Jun 2004

Adrenaline packs a powerful punch in the use of antidepressants

Researchers from the University of Pennsylvania School of Medicine found that norepinephrine (adrenaline) plays an important role in animals in determining behavioral effects in some of the most commonly prescribed antidepressants, regardless of which biochemical pathway the drug uses to alleviate symptoms of depression.

3 Jun 2004

Genes that allow nerve cells to communicate may have come from bacteria eons ago

Some of the genes that allow nerve cells and some other types of cells to send elaborate chemical messages to each other appear to have been transferred to animals or their immediate ancestors from bacteria eons ago.

2 Jun 2004

Brain cells containing the chemical histamine are critical for waking

A study by scientists with the Veterans Affairs' Neurobiology Research Laboratory and UCLA Neuropsychiatric Institute shows that brain cells containing the chemical histamine are critical for waking.

27 May 2004

Pregnancy massage may reduce the risk of premature births

Pregnancy massage long has been known to help expectant mothers feel better, and a new study shows it may well provide an even more important benefit – reducing the risk of premature births.

5 May 2004

Cymbalta helped patients with depression feel better

Patients treated successfully with 60 mg per day of the investigational antidepressant Cymbalta® (duloxetine hydrochloride), were less likely to have their emotional and physical symptoms of depression return than those who stopped taking medication after beginning to feel better

3 May 2004